News Column

ARIAD Reports First Quarter 2014 Financial Results and Development Progress

May 19, 2014

By a News Reporter-Staff News Editor at Pharma Business Week -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) reported financial results for the first quarter of 2014, including revenue from sales of IclusigŪ (ponatinib) and licensing agreements. The Company also provided an update on corporate developments (see also ARIAD Pharmaceuticals, Inc.).

"As we reintroduce Iclusig into the U.S. market and continue with the European launch this year, our key priorities are to rebuild confidence in Iclusig and to improve the benefit/risk profile of the drug," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Early launch data in the U.S. represent approximately 10 weeks of promotion with a revised product label and show strong market support for Iclusig from community and academic physicians and across a wide spectrum of patients with Philadelphia-positive leukemias. We are making solid progress in both the U.S. and European markets, giving us confidence in our full-year outlook for Iclusig. In addition, we have initiated a pivotal trial of AP26113 in patients with refractory non-small cell lung cancer." 2014 First Quarter Financial Results Revenues Total revenue for the quarter ended March 31, 2014 was $11.8 million, which includes product revenue from sales of Iclusig and license revenue.

Keywords for this news article include: ARIAD Pharmaceuticals Inc., Investment and Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Pharma Business Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters